Orthophosphate and Other Phosphate Compounds in Relation to Stone Formation

  • H. Fleisch
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 103)


It has been reported repeatedly that the ingestion of orthophosphate leads to a decrease in the formation of urinary calcium stones in man (1,2,3,4). The suggestion has therefore been made that stone formers may be treated by the administration of phosphate salts. Although some authors could not find such an effect (5), and even though a clearcut double-blind trial is still lacking, the bulk of evidence seems to suggest that such a beneficial effect is real. Now the question arises by what mechanism does this effect take place.


Calcium Phosphate Calcium Oxalate Urinary Stone Phosphate Compound Calcium Phosphate Precipitation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Howard, J.E.: Urinary stone. Canad.Med.Ass.J. 86: 1001, 1962.Google Scholar
  2. 2.
    Thomas, W.C., and Miller, G.H.: Inorganic phosphates in the treatment of renal calculi. Modern Treatment 4: 494, 1967.PubMedGoogle Scholar
  3. 3.
    Smith, L.H., Thomas, W.C., and Arnaud, C.D.: Orthophosphate therapy in calcium renal lithiasis. In: Urinary Calculi. S. Karger, Basel, 188, 1973.Google Scholar
  4. 4.
    Bernstein, D.S., and Newton, R.: The effect of oral sodium phosphate on the formation of renal calculi and on idiopathic hypercalciuria. Lancet, 1105, 1966.Google Scholar
  5. 5.
    Ettinger, B.: Recurrent nephrolithiasis: Natural history and effect of phosphate therapy. Amer.J.Med. 61: 200, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Robertson, W.G., Peacock, M., and Nordin, B.E.C.: Activity products in stone-forming and non-stone forming urine. Clin.Sci. 34: 579, 1968.Google Scholar
  7. 7.
    Pak, C.Y.C., and Chu, S.: A simple technique for the determination of urinary state of saturation with respect to brushite. Invest.Urol. 11: 211, 1973.PubMedGoogle Scholar
  8. 8.
    Pak, C.Y.C., Waters, O., Arnold, L.R., Holt, K., Cox, C., Barilla, D.: Mechanism for calcium urolithiasis among patients with hyperuricosuria: Supersaturation of urine with respect to monosodium urate. J.Clin. Invest., in press.Google Scholar
  9. 9.
    Robertson, W.G., Peacock, M., Marshall, R.W., Varna-vides, C.K., Heyburn, P.J., and Nordin, B.E.C.: Effect of oral orthophosphate on calcium crystalluria in stone-formers. In: Urolithiasis Research. Plenum Press, New York, 339, 1976.Google Scholar
  10. 10.
    Fleisch, H.: Inhibitors and promotors of stone formation. Kidney Int., in press.Google Scholar
  11. 11.
    Robertson, W.G., and Peacock, M.: Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin.Sci. 43: 499, 1972.PubMedGoogle Scholar
  12. 12.
    Fleisch, H., and Monod, A.: A new technique for measuring aggregation of calcium oxalate crystals in vitro: Effect of urine, magnesium, pyrophosphate and diphosphonates. In: Urinary Calculi. S. Karger, Basel, 53, 1973.Google Scholar
  13. 13.
    Hansen, N.M., Felix, R., Bisaz, S., and Fleisch, H.: Aggregation of hydroxyapatite crystals, Biochim. Biophys.Acta 451: 549, 1976.CrossRefGoogle Scholar
  14. 14.
    Robertson, W.G., Peacock, M., and Nordin, B.E.C.: Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin.Chim.Acta 43: 31, 1973.PubMedCrossRefGoogle Scholar
  15. 15.
    Felix, R., Monod, A., Broge, L., Hansen, N.M., and Fleisch, H.: Aggregation of calcium oxalate crystals: effect of urine and various inhibitors. Urol.Res. 5: 21, 1977.PubMedCrossRefGoogle Scholar
  16. 16.
    Gutman, A.B., and Yu, T.F.: Further studies of the relation between glycogenolysis and calcification in cartilage. In: Metabolic Interrelations. Josiah Macy Jr. Foundation, New York, 11, 1949.Google Scholar
  17. 17.
    Howard, J.E., and Thomas, W.C.: Some observations on rachitic rat cartilage of probably significance in the etiology of renal calculi. Trans.Amer.Clin.Chim. Ass. 70: 94, 1958.Google Scholar
  18. 18.
    Fleisch, H., and Bisaz, S.: The inhibitory effect of pyrophosphate on calcium oxalate precipitation and its relation to urolithiasis. Experientia 20: 276, 1964.PubMedCrossRefGoogle Scholar
  19. 19.
    Gill, W.B., and Karesh, J.W.: Demonstration of protective (inhibitory) effects of urinary macromolecules on the crystallization of calcium oxalate. In: Urolithiasis Research. Plenum Press, New York, 277, 1976.CrossRefGoogle Scholar
  20. 20.
    Pak, C.Y.C., Ohata, M., and Holt, K.: Effect of diphosphonate on crystallization of calcium oxalate in vitro. Kidney Int. 7: 154, 1975.PubMedCrossRefGoogle Scholar
  21. 21.
    Fleisch, H., and Bisaz, S.: Isolation from urine of pyrophosphate, a calcification inhibitor. Amer. J. Physiol. 203: 671, 1962.Google Scholar
  22. 22.
    Pak, C.Y.C., Hayashi, Y., Finlayson, B., and Chu, S.: Estimation of the state of saturation of brushite and calcium oxalate in urine: A comparison of three methods. J.Lab.Clin.Med. 89: 891, 1977.PubMedGoogle Scholar
  23. 23.
    Meyer, J.L., and Smith, L.H.: Growth of calcium oxalate crystals. I. A model for urinary stone growth. Invest.Urol. 13: 31, 1975.PubMedGoogle Scholar
  24. 24.
    Meyer, J.L., and Smith, L.H.: Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest.Urol. 13: 36, 1975.PubMedGoogle Scholar
  25. 25.
    Pak, C.Y.C., and Holt, K.: Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. Metabolism 25: 665, 1976.PubMedCrossRefGoogle Scholar
  26. 26.
    Bisaz, S., Felix, R., Fleisch, H., and Neuman, W.F.: Quantitative determination of inhibitors of calcium phosphate precipitation in whole urine. Mineral And Electr.Metab., in press.Google Scholar
  27. 27.
    Fleisch, H., and Neuman, W.F.: Mechanisms of calcification: Role of collagen, polyphosphates, and phosphatase. Amer.J.Physiol. 200: 1296, 1961.Google Scholar
  28. 28.
    Marshall, R.W., and Nancollas, G.H.: The kinetics of crystal growth of dicalcium phosphate dihydrate. J.Phys.Chem. 73: 3838, 1969.CrossRefGoogle Scholar
  29. 29.
    Fleisch, H., Russell, R.G.G., and Straumann, F.: Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212: 901, 1966.CrossRefGoogle Scholar
  30. 30.
    Lewis, A.M., Thomas, W.C., and Tornita, A.: Pyrophosphate and the mineralizing potential of urine. Clin. Sci. 30: 389, 1966.PubMedGoogle Scholar
  31. 31.
    Fleisch, H., and Bisaz, S.: Die Pyrophosphatausscheidung im Harn beim gesunden Menschen. Helv.Physiol. Pharm.Acta 21: 88, 1963.Google Scholar
  32. 32.
    Russell, R.G.G., and Hodgkinson, H.: Urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin.Sci. 31: 51, 1966.PubMedGoogle Scholar
  33. 33.
    Smith, L.H., Meyer, J.L., and McCall, I.T.: Chemical nature of crystal inhibitors isolated from human urine. In: Urinary Calculi. S. Karger, Basel, 318, 1973.Google Scholar
  34. 34.
    Mukai, T., and Howard, J.E.: Some observations on the calcification of rachitic cartilage by urine. Bull.Johns Hopkins Hospital 112: 279, 1963.Google Scholar
  35. 35.
    Meyer, J.L., and Nancollas, G.H.: Effect of stannous and fluoride ions on the rate of crystal growth of hydroxyapatite. J.Dent.Res. 51: 1443, 1972.PubMedCrossRefGoogle Scholar
  36. 36.
    Howard, J.E., Thomas, W.C., Barker, L.M., Smith, L.H. and Wadkins, C.L.: The recognition and isolation from urine and serum of a peptide inhibitor to calcification. Johns Hopkins Med.J. 120: 119, 1967.PubMedGoogle Scholar
  37. 37.
    Smith, L.H., and McCall, J.T.: Chemical nature of peptide inhibitors isolated from urine. In: Renal Stone Res. Symp., Churchill, 153, 1969.Google Scholar
  38. 38.
    Howard, J.E.: Studies on urinary stone formation: A saga of clinical investigation. Johns Hopkins Med.J. 139: 239, 1976.PubMedGoogle Scholar
  39. 39.
    Sutor, D.J.: Growth studies of calcium oxalate in the presence of various ions and compounds. Brit. J. Urol. 41: 171, 1969.PubMedCrossRefGoogle Scholar
  40. 40.
    Welshman, S.G., and McGeown, M.G.: A quantitative investigation of the effects on the growth of calcium oxalate crystals on potential inhibitors. Brit. J.Urol. 44: 677, 1972.PubMedCrossRefGoogle Scholar
  41. 41.
    Robertson, W.G., Knowles, F., and Peacock, M.: Urinary acid mucopolysaccharide inhibitors of calcium oxalate crystallization. In: Urolithiasis Research. Plenum Press, New York, 331, 1976.CrossRefGoogle Scholar
  42. 42.
    Fleisch, H., Russell, R.G.G., Bisaz, S., Termine, J.D., and Posner, A.S.: Influence of pyrophosphate on the transformation of amorphous to crystalline calcium phosphate. Calc.Tiss.Res. 2: 49, 1968.CrossRefGoogle Scholar
  43. 43.
    Francis, M.D.: The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calc.Tiss.Res. 3: 151, 1969.CrossRefGoogle Scholar
  44. 44.
    Jung, A., Bisaz, S., and Fleisch, H.: The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calc.Tiss.Res. 11: 269, 1973.CrossRefGoogle Scholar
  45. 45.
    Fleisch, H., Bisaz, S., and Care, A.D.: Effect of orthophosphate on urinary pyrophosphate excretion and the prevention of urolithiasis. Lancet, 1065, 1964.Google Scholar
  46. 46.
    Russell, R.G.G., Edwards, N.A., and Hodgkinson, A.: Urinary pyrophosphate and urolithiasis. Lancet, 1446,. 1964.Google Scholar
  47. 47.
    Russell, R.G.G., Bisaz, S., and Fleisch, H.: The influence of orthophosphate on the renal handling of inorganic pyrophosphate in man and dog. Clin.Sci. Mol.Med. 51: 435, 1976.PubMedGoogle Scholar
  48. 48.
    Baumann, J.M., Bisaz, S., Felix, R., Fleisch, H., Ganz, U., and Russell, R.G.G.: The role of inhibitors and other factors in the pathogenesis of recurrent calcium-containing renal stones. Clin.Sci.Mol.Med., in press.Google Scholar
  49. 49.
    Robertson, W.G., Peacock, M., Marshall, R.W., Marshall, D.H., and Nordin, B.E.C.: Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. New Engl. J.Med. 294: 249, 1976.PubMedCrossRefGoogle Scholar
  50. 50.
    Francis, M.D., Russell, R.G.G., and Fleisch, H.: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264, 1969.PubMedCrossRefGoogle Scholar
  51. 51.
    Fleisch, H.A., Russell, R.G.G., Bisaz, S., Mühlbauer, R.C., and Williams, D.A.: The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcifi- cation in vivo. Europ.J.Clin.Invest. 1: 12, 1970.PubMedCrossRefGoogle Scholar
  52. 52.
    Fraser, D., Russell, R.G.G., Pohler, O., Robertson, W.G., and Fleisch, H.: The influence of disodium ethane-l-hydroxy-1,1-diphosphonate (EHDP) on the development of experimentally induced urinary stones in rats. Clin.Sci. 42: 197, 1972.PubMedGoogle Scholar
  53. 53.
    Baumann, J.M., Bisaz, S., Fleisch, H., and Wacker, M.: Biochemical and clinical effects of ethane-lhydroxy-1,1-diphosphonate (EHDP) in calcium nephrolithiasis. Submitted.Google Scholar
  54. 54.
    Ohata, M., and Pak, C.Y.C.: Preliminary study of the treatment of nephrolithiasis (calcium stones) with diphosphonate. Metabolism 23: 1167, 1974.CrossRefGoogle Scholar
  55. 55.
    Robertson, W.G., Peacock, M., Marshall, W.R., and Knowles, F.: The effect of ethane-l-hydroxy-1,1diphosphonate (EHDP) on calcium oxalate crystalluria in recurrent renal stone-formers. Clin.Sci.Mol. Med. 47: 13, 1974.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • H. Fleisch
    • 1
  1. 1.Department of PathophysiologyUniversity of BerneBerneSwitzerland

Personalised recommendations